This unique initiative unites charity, academic and private sectors in the search for new dementia treatments.
The Dementia Consortium is a leading partnership programme between Alzheimer’s Research UK, Abbvie, Astex, Eisai, Lilly and MSD.
The initiative teams up leading researchers in universities across the world with UK-based drug discovery experts to develop their research findings into new treatments.
This approach allows promising projects to progressed towards the clinic, with the goal of delivering new treatments that will benefit people with dementia.
The Dementia Consortium funds research for novel targets and treatments for dementia including Alzheimer’s disease, dementia with Lewy bodies, frontotemporal dementia, plus Parkinson’s disease, amyotrophic lateral sclerosis and Huntington’s disease.
This global initiative runs in tandem with the UK-based Drug Discovery Alliance, making sure we leave no stone unturned in our search for new treatments.
By sustaining a healthy pipeline of potential new drugs for dementia, we will increase the likelihood of findings successful treatments that can transform lives. Our Global Clinical Trials Fund is positioned to make sure that potential new dementia treatments being developed through our drug discovery work have the opportunity to go into clinical testing in people – the final stage on the road to a new medicine.